©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.112944
Table 3 Adverse events, n (%)
| All (n = 124) | HAB (n = 26) | LAB (n = 98) | P value | |||||
| All | Grade 3 or more | All | Grade 3 or more | All | Grade 3 or more | All | Grade 3 or more | |
| 111 (90) | 51 (41) | 23 (88) | 14 (54) | 88 (90) | 37 (38) | 1.000 | 0.179 | |
| Neutropenia | 44 (35) | 30 (24) | 12 (46) | 12 (46) | 32 (33) | 18 (18) | 0.258 | 0.010 |
| Anaemia | 18 (15) | 7 (6) | 4 (15) | 3 (12) | 14 (14) | 4 (4) | 0.546 | 0.159 |
| Low platelet | 17 (14) | 6 (5) | 3 (12) | 2 (8) | 14 (14) | 4 (4) | 1.000 | 0.281 |
| Nausea | 30 (24) | 2 (2) | 5 (19) | 0 | 25 (26) | 2 (2) | 0.794 | 1.000 |
| Fatigue | 42 (34) | 1 (1) | 6 (23) | 0 | 36 (37) | 1 (1) | 0.246 | 1.000 |
| Anorexia | 34 (27) | 5 (4) | 6 (23) | 1 (4) | 28 (29) | 4 (4) | 0.631 | 1.000 |
| Peripheral sensory neuropathy | 49 (40) | 1 (1) | 6 (23) | 0 | 43 (44) | 1 (1) | 0.014 | 1.000 |
| Stomatitis | 6 (5) | 0 | 0 | 0 | 6 (6) | 0 | 0.342 | - |
| Diarrhoea | 20 (16) | 3 (2) | 2 (8) | 1 (4) | 18 (18) | 2 (2) | 0.240 | 1.000 |
| Constipation | 11 (9) | 0 | 0 | 0 | 11 (11) | 0 | 0.118 | - |
| Oedema | 6 (5) | 0 | 0 | 0 | 6 (6) | 0 | 0.583 | - |
| Allergy | 9 (7) | 7 (6) | 1 (4) | 1 (4) | 8 (8) | 6 (6) | 0.201 | 0.342 |
| Dysgeusia | 10 (8) | 0 | 2 (8) | 0 | 8 (8) | 0 | 0.714 | - |
| Infection | 10 (8) | 4 (3) | 3 (12) | 2 (8) | 7 (7) | 2 (2) | 0.395 | 0.281 |
| Hand-foot syndrome | 5 (4) | 0 | 0 | 0 | 5 (5) | 0 | 0.583 | - |
- Citation: Matsumoto T, Sugimoto S, Omori R, Makiyama C, Nakasya A, Nagai H, Yasui H, Higashi R, Sasamoto A, Satake H. Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites. World J Gastrointest Oncol 2026; 18(1): 112944
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/112944.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.112944